This article is more than 5 years old. Information may no longer be current.
VIDEO: ‘Disappointing’ LATITUDE–TIMI 60 data dash hopes for novel anti-inflammatory
CHICAGO — B. Hadley Wilson, MD, FACC, of the Sanger Heart & Vascular Institute, Carolinas HealthCare System in Charlotte, discusses findings from LATITUDE-TIMI 60, looking at the use of a novel anti-inflammatory agent to modify outcomes after an ACS.
Outlining the reasons for why reducing inflammation stands to benefit this population, Wilson details the design and “somewhat disappointing” results of the late-breaking clinical trial investigating losmapimod (GlaxoSmithKline), offering context from prior research.
“This agent has shown promise in other studies,” he said. “It may be that this could be tried again in a different constructed fashion. It also does not rule out trying other anti-inflammatory agents in this heart attack population.”